to first share of Executive second provide Seth us momentum value plan review evening our John as with of Chief Thank differentiated the Financial through hand guidance. for then on financial including highlights this in solutions results update open call you, a summary detailed the our our and Afterwards, take the business well market. I'll quarter to the Health. Chief strategic it Officer. drive themes across more from and Johnson, I'm how quarter partners. as I'll good the an I'll Blackley, a our joined Officer John Evolent key and evening. our by results, recent of I'm brief of
call. the we'll be always, happy As at take questions end the of to
the March total March and the XXXX quarter, quarter XXXX ended was $XXX.X quarter million. EBITDA for financial results In was XX, terms revenue the Adjusted overview million. ended $XX.X of the XX, for for
& Services approximately New guidance As as And the X.X Suite exceeded quarter. additional key increasing we for the Technology lives pleased John we we're on Century million Platform, our lives for of Overall, discuss we XX, on are million that XXXX, accordingly, will plus Health March later. our X.X objectives XXXX had Full an financial platform. our
outcomes an to plan. ability theme mid-teens risk-bearing Payers organic as and Now value-based based track to improve to of first on savings select of contribute new near-term providers and high-risk we that be open health will the to members the growth of create and our Today, respect announce our growth, patients. to to the With improve to care. and provide update towards with three Evolent growth. partnerships progress and two our strategic goals avenues new to on our our we of line quality our strong themes organic we'll continue capabilities continue against of utilize care excited solutions high-cost, our on cost top and target opportunity state-of-the-art we're
diagnosed with Century for Health has high-quality heart a patients primary application of who exciting leading the New cancer this of new New through ensure and primary risk-bearing care agreement health are First, risk-based clinics. specialty pathways. will an care network This partnership care entered groups into Century's disease with
reasons. later New about services markets, go-lives the cardiology several this with and to large oncology, and future. additional Century providing this two in both we radiation We're opportunities be partnership will in for excited for medical anticipate plans geographies oncology explore year, particularly
primary clinical the visibly to the and better has patients organization, care that and the this grow First, for a high-growth care and this relationship the value segment partnership for time. growing specialty We opportunity providers. is create intersection experience more them national opens over organization And unlock potential us. primary risk-bearing a second, believe to with the and creates of
plan health is an important today announcing a be in business, partnership large Health Services will our covers it for multiple and contributor we're partnership new us of and This second and markets signed with lines Evolent for The long-term solution. a XXXX agreement beyond.
during including services cardiology with Century the in an existing partnership South New quarter, Florida. same-store our adding Health to Additionally, growth we're efforts, pleased
see strong momentum our to see solutions we market. in in and our demand increasingly continue We in pipeline, the are
to environment trends for will the favorable care administration's the a are tailwind to to Additionally, in adoption cost-reducing the costs our the overall commitment measures, continue macro of accelerating be and health need solutions. control
and you four new eight Century, With look to two we nice see on of Evolent today, announced indicating balance new XXXX. our Further, last continue partnerships partnerships of our across the across solutions Partners year if back are across to towards XX track partners Care new welcomed six Evolent our expect partner new seven good and we announcements, to the portfolio this target Health future. the Services, New balance from from seven from into six for
EBITDA over costs strategic X.X% of traction benefits second scale lowering X.X%, our with seeing the of margin initiatives, across target Regarding including adjusted drive margins increase through theme, towards to XXXX. three goal customer of an we QX expanding driving our unit in business. our and nice all new of our mid-teens plan, areas continue our We're maturation
efficient month. closed Finally, with announced the Miami asset of beginning True to Plan sale at portfolio the Health Health New March. third closed of end to And transaction our the capital sales of want an allocation. provide The at the update I on Children's Mexico respect theme, and our previously
positive the had plan on health of completion we have exit these business deals, assets. successfully cumulative our our our of all Delivering line two and impact to health the monetized on commitment capital. exited has business a With this
business. will key conclusion, make progress on services accelerating capital EBITDA significant core on be forward, focus our allocation we focused In our three to continue within Going areas. our
that select payers Evolent management Turning discussed New evening, to platform, Century showcase we will Care our we our to quarter, updates. business Last the differentiators Partners. providers and Health. This drive specialty
Services. Care activities recent two our the Evolent and into we depth achievements other Health I Century, to of go solutions, want Before Evolent and in New highlight Partners
is opportunities Pathways total addressed with insight right evaluate committed on platform, to the more administration as critical partners. by panel well such allow to in physicians that Success management CMMI to weigh In bright profile in strong care of Evolent. Care features results carefully opportunities high-yield both continues perform These our and the Identifi, and will contracting participate for opportunity. new in we to and of We're Medicare, offering, deliver support to an our for using care. MSSP a future identifying compared Evolent our and economic with represents evergreen pause other Overall, more private prioritizing to Partners, new our business. continues cost and to QX contracting programs Furthermore, interventions. clinical and across the to as for outcome-centric we Evolent large ones tailwinds strong provide proprietary technology XXx Evolent continue ideas to payment and new model be direct and stakeholders a First, CMMI and network to support value-based Care and see private administration's Partners our XXXX. have the very payers, strategic XXXX, long-term QX With Medicare on respect ideal our models, with payers to successfully we opportunity believe
benchmarking with billion close in As public segment. $X premium, assets previously other we announced, to well already this in manage
investments well more our years. Medicare the and partners and tool, over markets product through few Importantly, as additional Advantage lives next the on in we commercial existing our see development, our markets Panel lives will discussed opportunities Market manage more as such to Insight increase previously expansion in contracts. add as community-based impact
payers administrative our Services, Health cost the on to in simplification the patients' Evolent Second, lessen modernization enrich invest offering, we lives providers that and and to burden serve. and continues
the in text disease with We administrative market. diabetes, clinical operational as receiving The are Maryland high-quality continue utilizes three-pronged Recently, currently the partner success margin U.S. Care Evolent through in Health launched strategy the to to automation partner our differentiators $X see ahead. create they and COVID and The outcomes chronic an further schedule, team our years such the and focus to management along robotic disease, innovation, membership architecture, industry-leading, awareness category a to health for cloud-first access vaccine as to Physicians accelerate implemented assessment product educated strategy are subpopulations, efficiency the the for commitment that integrated trillion outreach practice the in sales AI platform care access be cost our our intends services also vaccine. should and efforts. end-stage and and on platform spending. processing those outreach to and assist and will of us These email hemodialysis. and help to with respiratory an including largest the our prioritized and actually campaigns, on have membership's based of our part savings care members vaccine. of administrative in most Investing in those our and state to the of is with And out continue and renal in fully at-risk cancer, XXXX module savings The Maryland's rollout intervention differentiation ensure XXXX cost waste is yield Evolent, and drive in marketplace. across and
The the Finally, New and across Century market Health strong to in underpin see provider high experienced of high new both as New in the and at recent risk-bearing in complexity for and and also same-store services. end able increasingly of oncology our light the uptick pandemic cost business continue tunnel. terms the demand cardiology to engagement continues the growth. a plan We've Century health to are grow prospects
I to you programs and partners and here. members. or further Health three enhancements support want in their those Century with invest continues of patients to share New our new to Additionally, technology
policies. First, and prior impact their new in several including drug reviews, model January, authorization to new New plans their policies, of Century the help launched optimize services drug
pathways, launch to the clinical supporting with evidence the money emphasis module treating our the receive Century oncologists lower the and that encourage there broad are to situations on preferred patients a clear Next, will module and the sequencing time risk specific of with wasting gene patients first-line enables we're use enable in where in of latest benefits. appropriate next-generation of to to therapy us deepen an teams help therapy. panel most genomics increasing excited us new the New confidence oncology Health our incorporate and and best and select pathways their also the in in failed This a tests. announce module This
are therapies initiative this the to appropriate ensure also trials. clinical cancer Beyond subsequent patient's that for will mutation, genetic identify given candidates helping
even for care receiving our market this critical in for Q&A, With a been of want share enhancements platform four X Level three that CarePro, work Century. the the that New a architecture, finally, in in Once optimal science and from pathways the new a are patients are add-on platform, to I strategically us often the simplified in in including hard Health expansion addition is care. of platform, To the will include or market, not believe, is patient we've of New Century you improvement pathways in to a means that ability receiving. to for see rate of enhancements, out future of impact new care. how development range, XX, also material we a or these And team has strong the The new we primary cardiology believe even range. the adherence accelerating impact figure enter allow rate of the mid-XX% the our of XX of Often, high we services our to find in XX% that XX% months, believe That service-first the in patients been treatments, effect very solution. request. is and the module at the state-of-the-art cumulative we when we give impacts live sense a to
payer, clients that called oncologist complicated case oncologist, and real course of Century adherence by one to one you had with a is the B-cell this of the reviewed a the normal increase treating in large pathway support. care life from to we patients for patient. bring diagnosed how the the Health, service therefore patient Recently, me lymphoma. example quality The what our Let the cancer giving we of and New of the
adjust oncologists form approval and, of made Kymriah, is with the the called this drug had intervene patient of lymphoma part is diagnosis work able fact, consulted and CNS patient. the to sick different oncologist been called therapy or been drug the from at lethal the our requested, Kymriah, it by we on a actually a lymphoma the oncologist patient. had patient Century for Thanks to for After the our treating have incredibly New contraindicated with the to the could diagnosis, Novartis. to have New The would made case, that brand of and CNS. Century, to patient team As in were and requested treat found possibly patient nurses treatment CAR-T misdiagnosed a that which
patient's As There's every system cost to and our will today now care to story work, day to $X.X that's side to people a wanting health million the who the the management family because be because come improved. Evolenteers in XX a investments it my help like. to result, a to insurance an make of premiums, the materially care effect, other impact. better and additional shared has $X million work million of me And and this funding lower off I inspires payer the as next through lower outlook $X across the up likely fellow months. much
day example at every across New Century. kind interventions one just of make and we Evolent of that Of the course, patients all this our of is
of increase I go pathway to and patients we we're way while just can very Finally, help materially proud the described, further. do we the adherence in work
additional ahead indicator Our just cardiology of as I'll that, and pathway Century continue also long-term invest, give as believe move With for ambition is Health. details we QX map is turn it provide to an how John but for to performance opportunity to a guidance. goal oncology future financial over well how adherence on big XX%. we'll both for lies our a New road over That to
